Form 4 for EYPT EyePoint, Inc.
Accepted 2024-01-24 00:00:00 ET · period of report 2024-01-22 · accession 0001562180-24-000581 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-24 | 2024-01-22+ | EYPT | Jones David Scott | SVP, Chief Commercial Off | M - OptEx | $10.27 | +35.1K | 38.4K | +1,064% | +$360.1K |
| DM | 2024-01-24 | 2024-01-22+ | EYPT | Jones David Scott | SVP, Chief Commercial Off | S - Sale+OE | $22.68 | -35.1K | 38.0K | -48% | -$795.3K |
| DM | 2024-01-24 | 2024-01-22+ | EYPT | Jones David Scott | SVP, Chief Commercial Off | M - OptEx | $0.00 | -35.1K | 4,584 | -88% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-22 | M | A | 5,416 | $11.47 | 72,128 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-22 | S | D | 5,416 | $22.24 | 66,712 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-01-22 | S | D | 28,750 | $22.69 | 37,962 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2024-01-23 | M | A | 500 | $3.26 | 38,862 | D | — | — | |
| 5 | Common | Common Stock | 2024-01-23 | S | D | 400 | $25.00 | 38,462 | D | — | — | |
| 6 | Common | Common Stock | 2024-01-23 | S | D | 500 | $25.00 | 37,962 | D | — | — | |
| 7 | Common | Common Stock | 2024-01-22 | M | A | 28,750 | $10.13 | 66,712 | D | — | — | |
| 8 | Common | Common Stock | 2024-01-23 | M | A | 400 | $12.90 | 38,362 | D | — | — | |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-01-23 | M | D | 500 | $0.00 | 91,155 | D | $3.26 · — to 2033-01-05 | 500 Common Stock | (F6) The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. |
| 10 | Derivative | Stock Option (Right to Buy) | 2024-01-22 | M | D | 28,750 | $0.00 | 31,250 | D | $10.13 · — to 2032-02-09 | 28,750 Common Stock | (F4) The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years. |
| 11 | Derivative | Stock Option (Right to Buy) | 2024-01-23 | M | D | 400 | $0.00 | 24,225 | D | $12.90 · — to 2030-02-28 | 400 Common Stock | (F5) The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 |
| 12 | Derivative | Stock Option (Right to Buy) | 2024-01-22 | M | D | 5,416 | $0.00 | 4,584 | D | $11.47 · — to 2031-11-01 | 5,416 Common Stock | (F3) The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. |